Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (231-240 of 442) with videos related to

Pageof 45
Sort By:
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Molecular Cancer Therapeutics|March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental TherapiesRoman Groisberg, Jason Roszik, Anthony P Conley, et al.
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Investigational New Drugs|June 13, 2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Contemporary Clinical Trials Communications|October 3, 2022
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerationsW Katherine Tan, Brian D Segal, Melissa D Curtis, et al.
Melanoma Research|June 16, 2023
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case reportKewen He, David S Hong, Danxia Ke, et al.
Oncotarget|August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsJ Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsDavid S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Pageof 45

Showing results (231-240 of 442) with videos related to

Sort By:
Pageof 45
Clinical Colorectal Cancer|May 22, 2026
Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal CancerLisa Salvatore, Marwan Fakih, Yasutoshi Kuboki, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Molecular Cancer Therapeutics|March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental TherapiesRoman Groisberg, Jason Roszik, Anthony P Conley, et al.
The Lancet. Oncology|April 22, 2014
MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion studyDavid S Hong, David Hui, Eduardo Bruera, et al.
Cancer Chemotherapy and Pharmacology|March 11, 2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumorsAnthony W Tolcher, Jordan D Berlin, Jan Cosaert, et al.
Investigational New Drugs|June 13, 2013
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancerPrasanth Ganesan, Sarina Piha-Paul, Aung Naing, et al.
Contemporary Clinical Trials Communications|October 3, 2022
Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerationsW Katherine Tan, Brian D Segal, Melissa D Curtis, et al.
Melanoma Research|June 16, 2023
Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case reportKewen He, David S Hong, Danxia Ke, et al.
Oncotarget|August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsJ Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2024
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterationsDavid S Hong, Federico Cappuzzo, Byoung Chul Cho, et al.
Pageof 45